Replies to post #243596 on Amarin Corp Plc (AMRN)

[HDGabor]

a-

You’re using hindsight; nobody believed Jelis was reliable until after Reduce It. Open label, poor compliance, improper statin doses, high baseline epa levels.... The group treated in Jelis is not high risk enough.

You are way-off … e.g.:

- open label: it was not fully open … adjudication was fully blinded (" blinded clinical endpoint assessment (PROBE design)"
- poor compliance: The 5-year follow-up rate was 16 971 (91%). Similar proportions of participants remained compliant in each treatment group.

Hindsight ??? It could not exist on 07/24/18 … So I ask myself: could the active arm of R-IT reach / be near to the Japanese risk level due to 4g/day EPA … and the answer was: yes

It’s better to keep your mouth shut and appear stupid than open it and remove all doubt ...

[ziploc_1]

anfla...The Japanese diet contains more fish than most diets around the world...This makes for a higher concentration of EPA in the Japanese population and makes the 1.8 grams of EPA used in Jelis similar to the 4 grams of EPA in R-IT...in populations with diets,which don't include so much fish...I was disappointed when the FDA did not accept the results of Jelis and insisted on the R-IT study to prove the effectiveness of Vascepa.

[Dancing in the dark]

great wealth bestowed upon many of those non-believers who inhabit this board